The Swiss molecular diagnostics company, Biocartis SA, has raised €71 million in a Series C round to support the development of its products including an integrated diagnostic that is expected to be launched in 2013. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
